Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112


Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer.

Jeong W, Kim SB, Sohn BH, Park YY, Park ES, Kim SC, Kim SS, Johnson RL, Birrer M, Bowtell DSL, Mills GB, Sood A, Lee JS.

Anticancer Res. 2014 Feb;34(2):811-817.


Inactivation of Hippo Pathway Is Significantly Associated with Poor Prognosis in Hepatocellular Carcinoma.

Sohn BH, Shim JJ, Kim SB, Jang KY, Kim SM, Kim JH, Hwang JE, Jang HJ, Lee HS, Kim SC, Jeong W, Kim SS, Park ES, Heo J, Kim YJ, Kim DG, Leem SH, Kaseb A, Hassan MM, Cha M, Chu IS, Johnson RL, Park YY, Lee JS.

Clin Cancer Res. 2016 Mar 1;22(5):1256-64. doi: 10.1158/1078-0432.CCR-15-1447. Epub 2015 Oct 12.


Expression of Yes-associated protein 1 and its clinical significance in ovarian serous cystadenocarcinoma.

Cho SY, Kim K, Park MS, Jang MY, Choi YH, Han S, Shin HM, Chung C, Han HY, Yang JB, Ko YB, Yoo HJ.

Oncol Rep. 2017 May;37(5):2620-2632. doi: 10.3892/or.2017.5517. Epub 2017 Mar 21.


Overexpression of the YAP1 oncogene in clear cell renal cell carcinoma is associated with poor outcome.

Rybarczyk A, Klacz J, Wronska A, Matuszewski M, Kmiec Z, Wierzbicki PM.

Oncol Rep. 2017 Jul;38(1):427-439. doi: 10.3892/or.2017.5642. Epub 2017 May 15.


Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients.

Lee KW, Lee SS, Kim SB, Sohn BH, Lee HS, Jang HJ, Park YY, Kopetz S, Kim SS, Oh SC, Lee JS.

Clin Cancer Res. 2015 Jan 15;21(2):357-64. doi: 10.1158/1078-0432.CCR-14-1374. Epub 2014 Nov 11.


Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis.

Kang W, Tong JH, Chan AW, Lee TL, Lung RW, Leung PP, So KK, Wu K, Fan D, Yu J, Sung JJ, To KF.

Clin Cancer Res. 2011 Apr 15;17(8):2130-9. doi: 10.1158/1078-0432.CCR-10-2467. Epub 2011 Feb 23.


Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response.

Lehn S, Tobin NP, Sims AH, Stål O, Jirström K, Axelson H, Landberg G.

BMC Cancer. 2014 Feb 22;14:119. doi: 10.1186/1471-2407-14-119.


The Hippo Pathway as Drug Targets in Cancer Therapy and Regenerative Medicine.

Nagashima S, Bao Y, Hata Y.

Curr Drug Targets. 2017;18(4):447-454. doi: 10.2174/1389450117666160112115641. Review.


The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer.

Song S, Honjo S, Jin J, Chang SS, Scott AW, Chen Q, Kalhor N, Correa AM, Hofstetter WL, Albarracin CT, Wu TT, Johnson RL, Hung MC, Ajani JA.

Clin Cancer Res. 2015 Jun 1;21(11):2580-90. doi: 10.1158/1078-0432.CCR-14-2191. Epub 2015 Mar 4.


Genetic variants in Hippo pathway genes YAP1, TEAD1 and TEAD4 are associated with melanoma-specific survival.

Yuan H, Liu H, Liu Z, Zhu D, Amos CI, Fang S, Lee JE, Wei Q.

Int J Cancer. 2015 Aug 1;137(3):638-45. doi: 10.1002/ijc.29429. Epub 2015 Jan 28.


Cytoplasmatic and Nuclear YAP1 and pYAP1 Staining in Urothelial Bladder Cancer.

Latz S, Umbach T, Goltz D, Kristiansen G, Müller SC, Ellinger J.

Urol Int. 2016;96(1):39-45. doi: 10.1159/000438868. Epub 2015 Aug 20.


Low angiomotin-p130 with concomitant high Yes-associated protein 1 expression is associated with adverse prognosis of advanced gastric cancer.

Hong SA, Son MW, Cho J, Jang SH, Lee HJ, Lee JH, Cho HD, Oh MH, Lee MS.

APMIS. 2017 Nov;125(11):996-1006. doi: 10.1111/apm.12750. Epub 2017 Sep 8.


microRNA 31 functions as an endometrial cancer oncogene by suppressing Hippo tumor suppressor pathway.

Mitamura T, Watari H, Wang L, Kanno H, Kitagawa M, Hassan MK, Kimura T, Tanino M, Nishihara H, Tanaka S, Sakuragi N.

Mol Cancer. 2014 Apr 29;13:97. doi: 10.1186/1476-4598-13-97.


The Hippo Signaling Pathway Regulates Ovarian Function via the Proliferation of Ovarian Germline Stem Cells.

Ye H, Li X, Zheng T, Hu C, Pan Z, Huang J, Li J, Li W, Zheng Y.

Cell Physiol Biochem. 2017;41(3):1051-1062. doi: 10.1159/000464113. Epub 2017 Feb 27.


Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer.

Oh SC, Park YY, Park ES, Lim JY, Kim SM, Kim SB, Kim J, Kim SC, Chu IS, Smith JJ, Beauchamp RD, Yeatman TJ, Kopetz S, Lee JS.

Gut. 2012 Sep;61(9):1291-8. doi: 10.1136/gutjnl-2011-300812. Epub 2011 Oct 13.


Nuclear expression of Yes-associated protein 1 correlates with poor prognosis in intestinal type gastric cancer.

Song M, Cheong JH, Kim H, Noh SH, Kim H.

Anticancer Res. 2012 Sep;32(9):3827-34.


Effects of the hippo signaling pathway in human gastric cancer.

Zhou GX, Li XY, Zhang Q, Zhao K, Zhang CP, Xue CH, Yang K, Tian ZB.

Asian Pac J Cancer Prev. 2013;14(9):5199-205.


Prognostic Value of Yes-Associated Protein 1 (YAP1) in Various Cancers: A Meta-Analysis.

Sun Z, Xu R, Li X, Ren W, Ou C, Wang Q, Zhang H, Zhang X, Ma J, Wang H, Li G.

PLoS One. 2015 Aug 11;10(8):e0135119. doi: 10.1371/journal.pone.0135119. eCollection 2015.


miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer.

Pan Y, Robertson G, Pedersen L, Lim E, Hernandez-Herrera A, Rowat AC, Patil SL, Chan CK, Wen Y, Zhang X, Basu-Roy U, Mansukhani A, Chu A, Sipahimalani P, Bowlby R, Brooks D, Thiessen N, Coarfa C, Ma Y, Moore RA, Schein JE, Mungall AJ, Liu J, Pecot CV, Sood AK, Jones SJ, Marra MA, Gunaratne PH.

Oncotarget. 2016 May 3;7(18):25930-48. doi: 10.18632/oncotarget.8412. Erratum in: Oncotarget. 2017 Mar 7;8(10 ):17406.


Yes-associated protein 1 (YAP1) promotes human gallbladder tumor growth via activation of the AXL/MAPK pathway.

Li M, Lu J, Zhang F, Li H, Zhang B, Wu X, Tan Z, Zhang L, Gao G, Mu J, Shu Y, Bao R, Ding Q, Wu W, Dong P, Gu J, Liu Y.

Cancer Lett. 2014 Dec 28;355(2):201-9. doi: 10.1016/j.canlet.2014.08.036. Epub 2014 Sep 10.


Supplemental Content

Support Center